Related Experiment Videos
[Immunoglobulin therapy for systemic lupus erythematosus]
N Utku1, J von Kempis, J K Rockstroh
1Medizinische Klinik, Universität Bonn.
Immunitat Und Infektion
|April 1, 1993
Summary
This case study highlights a lupus erythematosus patient experiencing treatment-resistant myositis and erythema. High-dose intravenous immunoglobulin therapy effectively resolved skin erythema, offering a potential treatment avenue.
Area of Science:
- Rheumatology
- Dermatology
- Clinical Immunology
Background:
- Lupus erythematosus (LE) management can be complex, with patients sometimes exhibiting refractory symptoms.
- Chloroquine therapy was initially used for a patient with LE presenting with myositis and skin erythema.
Observation:
- The patient experienced worsening myositis despite treatment with cyclophosphamide and prednisolone.
- Methotrexate led to hepatotoxicity, and azathioprine resulted in leukopenia and sepsis.
- Persistent skin erythema prompted consideration of alternative therapies.
Findings:
- High-dose intravenous immunoglobulin (IVIg) therapy was administered due to persistent erythema unresponsive to multiple immunosuppressants.
- Significant improvement in skin erythema was observed within 10 days of IVIg treatment.
- The positive response to IVIg was sustained for approximately 4 months, even after dose reduction.
Implications:
- Intravenous immunoglobulin may represent a viable therapeutic option for recalcitrant cutaneous manifestations in lupus erythematosus.
- This case underscores the challenges in managing complex LE cases and the need for personalized treatment strategies.
- Further research into IVIg efficacy for specific lupus erythematosus subtypes and symptoms is warranted.